Bethan Psaila, MBBS, MRCP, FRCPath, PhD, University of Oxford, Oxford, UK, discusses the future prospects of immunotherapy in myeloproliferative neoplams (MPNs), highlighting current research on novel targets that might selectively be expressed in the mutant clone of hematopoietic stem cells. This interview took place at the Myeloproliferative Neoplasms Advances Day 2019 in London, UK.

свернуть